Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Tinidazole for Refractory Trichomonas Vaginitis
NCT05383521Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tinidazole (2 arms). Primary endpoint: Cure rate of refractory trichomoniasis at 24 weeks. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
tinidazole
Beyond the preview
Go deeper on NCT05383521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383521.